Parsatuzumab is a monoclonal antibody that targets the human protein CD20, which is primarily expressed on the surface of B cells. This characteristic makes it particularly relevant in the treatment of certain B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. As a therapeutic agent, Parsatuzumab functions by binding to CD20, leading to the destruction of B cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The CAS number 1312797-14-0 uniquely identifies this compound in chemical databases, facilitating its study and regulation. Monoclonal antibodies like Parsatuzumab are typically produced using recombinant DNA technology, ensuring specificity and efficacy in targeting disease-related cells. The development and clinical application of such antibodies represent a significant advancement in targeted cancer therapies, offering a more precise approach compared to traditional chemotherapy. As with many biologics, the safety and efficacy of Parsatuzumab are evaluated through rigorous clinical trials before it can be approved for widespread clinical use.

Parsatuzumab

1312797-14-0: Parsatuzumab is a monoclonal antibody that targets the human protein CD20, which is primarily expressed on the surface of B cells. This characteristic makes it particularly relevant in the treatment of certain B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. As a therapeutic agent, Parsatuzumab functions by binding to CD20, leading to the destruction of B cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The CAS number 1312797-14-0 uniquely identifies this compound in chemical databases, facilitating its study and regulation. Monoclonal antibodies like Parsatuzumab are typically produced using recombinant DNA technology, ensuring specificity and efficacy in targeting disease-related cells. The development and clinical application of such antibodies represent a significant advancement in targeted cancer therapies, offering a more precise approach compared to traditional chemotherapy. As with many biologics, the safety and efficacy of Parsatuzumab are evaluated through rigorous clinical trials before it can be approved for widespread clinical use.

Parsatuzumab (RG 7414), a monoclonal antibody targeting EGFL7, an immunomodulator.Parsatuzumab inhibits the interaction of EGFL7 with endothelial cells.

<p>Anti-Human EGFL7 Monoclonal Antibody</p>

CAS 1312797-14-0

Parsatuzumab

Parsatuzumab

Ref: TM-T76756

Parsatuzumab

Ref: 3D-CLA1310